Novartis to discuss considerations and critical success factors in ADC development

Top Quote SMi reports : Specialists from Novartis to speak on ADC development at the 5th ADC Summit in London. End Quote
  • (1888PressRelease) February 16, 2016 - London UK : Lead specialists from Novartis are set to discuss challenges and lessons learnt from recent developments of antibody drug conjugates at the 5th ADC Summit in London on 23 - 24 May 2016. The two-day event provides a comprehensive analysis of the various approaches with the next generation ADCs led by industry experts including Roche, Takeda, Pfizer, AstraZeneca, Bayer and more. Visit for more information.

    Jens Lohrmann, Senior Global Program Manager for Translational Clinical Oncology will be presenting about the challenges and lessons learnt in ADC CMC development and outsourcing. He will cover the following topics:
    Buy vs make: considerations and critical success factors
    Scale-up and site transfer of a conjugation process with impact on key product quality attributes
    Analytical transfers: considerations and lessons from a challenging assay transfers.

    Carl Uli Bialucha, Senior Investigator I for Oncology Biotherapeutics, will present about "Targeting Cadherin-6 with a novel ADC for the treatment of ovarian and renal cancers". His session will discuss
    ADC lead selection covering optimal choice of antibody and linker/payload
    PK/PD studies to evaluate MoA and projected efficacious dose
    Population-scale in vivo assessment in ovarian cancer PTX clinical trial.

    Other key presentations include:
    ADCETRIS developed to treat Hodgkin Lymphoma
    Ashish Gautam, Global Medical Lead - ADCETRIS, Takeda
    Predicting tissue distribution and clearance of antibody formats to improve selectivity of targeted therapies
    Ben-Fillippo Krippendeorff, Principal Scientist, Roche
    Impact of drug loading on ADC target binding and cytotoxicity
    Debbie Meyer, Senior Principal Scientist, Pfizer
    The design, synthesis and scale-up of an ADC tubulysin
    Jeremy Parker, Principal Scientist, Pharmaceutical Development, AstraZeneca and many more.

    Visit to view the full speaker lineup.

    In addition to the conference, the event will feature two exclusive half-day post-conference workshops held on the 25 May 2016:
    1. ADC payloads: Availability and mechanisms of action
    Hosted by Femtogenix and King's Cross London
    2. Developments in high potency API manufacturing
    Hosted by SKAN AG

    For more information or to register visit the event website at An Early Bird discount of 400 applies to all bookings made by 29 February.

    For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick ( @ ) smi-online dot co dot uk dot

    For group/delegate bookings contact Fateja Begum on +44 (0) 20 7827 6184 or email fbegum ( @ ) smi-online dot co dot uk dot

    For media enquiries contact Honey de Gracia on +44 (0) 20 7827 6102 or email hdegracia ( @ ) smi-online dot co dot uk dot

    5th ADC Summit
    23-24 May 2016
    London, UK
    Contact e-mail: hdegracia ( @ ) smi-online dot co dot uk
    Contact number: +44 (0) 207 827 6102
    Event Website:

    About SMi Group:
    Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

  • FB Icon Twitter Icon In-Icon
Contact Information